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Aberrant Cdk5 Activation by p25 Triggers
Pathological Events Leading to
Neurodegeneration and Neurofibrillary Tangles
cated form of p35, p25. p25 is fully capable of activating
Cdk5; however, p25 is more stable and displays a differ-
ent subcellular localization than p35. Although conflict-
ing reports exist as to whether p25 levels are increased
in AD brains (Taniguchi et al., 2001; Tseng et al., 2002;
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Yoo and Lubec, 2001), we hypothesized that p25 causes2 Howard Hughes Medical Institute
aberrant activation of Cdk5, which, in turn, contributes200 Longwood Avenue
to neurodegeneration. We and others found that in pri-Boston, Massachusetts 02115
mary neurons, p25 is produced by calpain cleavage of
p35 between residues 98 and 99 upon neurotoxic insults,
including oxidative stress, excitoxicity, and-amyloid (A)Summary
peptide treatment (Kusakawa et al., 2000; Lee et al.,
2000; Nath et al., 2000). Overexpression of p25 in cul-Cyclin-dependent kinase 5 (Cdk5) and its regulatory sub-
tured cortical neurons results in disruption of cytoskele-unit p35 are integral players in the proper development
ton, hyperphosphorylation of tau, and apoptotic cellof the mammalian central nervous system. Proteolytic
death, indicating that aberrant Cdk5 activation is neuro-cleavage of p35 generates p25, leading to aberrant
toxic. Pharmacological inhibition of Cdk5 also attenu-Cdk5 activation. The accumulation of p25 is implicated
ates neurotoxicity resulting from A peptide treatmentin several neurodegenerative diseases. In primary neu-
(Alvarez et al., 2001; Lee et al., 2000). In addition, p35 torons, p25 causes apoptosis and tau hyperphosphory-
p25 conversion can be induced by A peptide treatmentlation. Current mouse models expressing p25, how-
(Lee et al., 2000; Li et al., 2003; Town et al., 2002). Theseever, fail to rigorously recapitulate these phenotypes in
observations, in conjunction with the findings that, invivo. Here, we generated inducible transgenic mouse
mutant APP transgenic (Tg) mice, A induces Cdk5-lines overexpressing p25 in the postnatal forebrain.
dependent tau phosphorylation that is accompanied byInduction of p25 preferentially directed Cdk5 to patho-
p25 accumulation (Otth et al., 2002), suggest that p25/logical substrates. These animals exhibited neuronal
Cdk5 may mediate the neurotoxic effect of A on tauloss in the cortex and hippocampus, accompanied by
phosphorylation.forebrain atrophy, astrogliosis, and caspase-3 activa-
Cdk5 was originally identified as a major tau kinasetion. Endogenous tau was hyperphosphorylated at
(Baumann et al., 1993; Paudel et al., 1993) and has beenmany epitopes, aggregated tau accumulated, and neu-
shown to be associated with early stages of neurofibril-rofibrillary pathology developed progressively in these
lary tangles (NFTs) (Augustinack et al., 2002; Pei et al.,animals. Our cumulative findings provide compelling
1998), one of the pathological hallmarks of neurodegen-evidence that in vivo deregulation of Cdk5 by p25 plays
erative tauopathies and AD composed mainly of hyper-a causative role in neurodegeneration and the devel-
phosphorylated tau aggregates. Triple transgenic (Tg)opment of neurofibrillary pathology.
mice overexpressing human p35, Cdk5, and tau, despite
significant increases in Cdk5 activity in these mice, doIntroduction
not display an increase in tau phosphorylation (Van den
Haute et al., 2001). These findings indicate that p35/Cyclin-dependent kinase 5 (Cdk5) is a proline-directed
Cdk5 does not efficiently phosphorylate tau. This notionprotein kinase that phosphorylates serine and threonine
is further corroborated by the report that recombinant
residues. As monomeric Cdk5 displays no enzymatic
p25/Cdk5 phosphorylates tau with higher efficiency than
activity, an interaction with either p35 or p39, two pro-
p35/Cdk5 in vitro (Hashiguchi et al., 2002). In addition,
teins abundantly expressed in postmitotic neurons, is the recent study describing the expression of human
necessary for Cdk5 activation (Lew et al., 1994; Tang et mutant P301L tau with p25 in double Tg mice shows
al., 1995; Tsai et al., 1994). Cdk5 is a pleiotropic kinase increased tau phosphorylation and aggregation into fila-
that plays numerous functions in the mammalian central ments (Noble et al., 2003).
nervous system (Dhavan and Tsai, 2001). The most well- Together, these observations suggest that generation
characterized role of Cdk5 is its involvement in the de- and accumulation of p25 causes neuronal death, alters
velopmental regulation of cortical development (Gupta the substrate specificity of Cdk5, results in the hyper-
et al., 2002). phosphorylation of tau, and is involved in the develop-
Increased Cdk5 activity has been observed in several ment of neurofibrillary pathology. To test this hypothesis
neurodegenerative diseases including Alzheimer’s dis- in vivo, we created inducible mouse lines overexpress-
ease (AD) and animal models of amyotrophic lateral scle- ing p25 in the postnatal forebrain. Here, we provide
rosis (ALS) and Niemann Pick type C (NPC) disease (Bu direct evidence for a role of p25 in neurodegeneration
et al., 2002; Lee et al., 1999; Nguyen et al., 2001; Patrick and tau pathology in the cortex and hippocampus of
et al., 1999). In all of these cases, the increase in Cdk5 mice. We show that p25 overexpression results in sub-
activity is accompanied by the accumulation of a trun- stantial brain atrophy, progressive neuronal loss, hyper-
phosphorylation/aggregation of tau, and NFT-like pa-
thology. Interestingly, while the phosphorylation of tau*Correspondence: jonathan_cruz@hms.harvard.edu
3These authors contributed equally to this work. and other Cdk5 substrates, such as neurofilaments (NF)
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and APP, is upregulated, the phosphorylation of known lalle et al., 1997; Tomizawa et al., 1996), p25 did not
label axonal fiber tracts in the forebrain (data not shown).physiological Cdk5 substrates is not increased in p25
Tg mice. Our results indicate that p25 may redirect Cdk5
to alternative substrates involved in neurodegeneration. Neurodegeneration in p25 Tg Mice
Our findings also support the concept that neurodegen- Induced p25 Tg mice compared to control littermates
eration and tau pathology can be a consequence of exhibited a slightly decreased body weight. Upon gross
pathogenic p25/Cdk5 activation and highlight the signif- inspection of brains from control and p25 Tg mice, we
icance of protein phosphorylation in the progression of found a significant decrease in forebrain mass in Tg
neurodegenerative diseases. mice (Figure 2A). In addition, we detected a progressive
decrease in brain weight of Tg mice induced for various
periods of time (Figure 2B, see Supplemental Figure S1CResults
at http://www.neuron.org/cgi/content/full/40/3/471/DC1).
As compared to control mice, Tg mice induced for 5Generation of Inducible Tg Mice Overexpressing
weeks had a 15%–20% decrease in brain weight; afterp25 in the Postnatal Forebrain
7–8 weeks or 12 weeks of p25 induction, there was aWe used the tetracycline-controlled transactivator (tTA)
30% decrease in brain weight. We next examined thesystem to generate bitransgenic mice that inducibly over-
histology of noninduced and induced Tg animals. Nissl-express human p25 under the control of the CamKII
stained brain sections from noninduced and 12 weekpromoter, which drives high transgene expression in the
induced Tg littermates revealed considerable decreasesforebrain (Mayford et al., 1996). In the presence of the
in the thickness and neuronal density within the cerebraltetracycline derivative doxycycline, expression of the p25
cortex and hippocampus of induced Tg mice (Figuretransgene is inhibited. All mice in this study were con-
2C). To further assess if there was neuronal loss in theseceived and raised in the presence of doxycycline for at
brain regions of Tg mice, we immunostained mouseleast 4–6 weeks postnatal before induction of p25 to
brain sections with the neuronal-specific markers NeuNprevent any potential developmental consequences
and HuC/D. Progressive neuronal loss was found in bothfrom the expression of p25.
the cerebral cortex (Figure 2D) and hippocampus (FigureTo date, no antibody has been successfully generated
2E) of Tg mice. Further quantification of these resultsthat specifically recognizes p25 but not p35. In order to
(Figure 2F, and see Supplemental Figure S1D at http://unambiguously distinguish p25 from endogenous p35,
www.neuron.org/cgi/content/full/40/3/471/DC1)we C-terminally tagged p25 with either GFP or Cmyc.
revealed that, as compared to control mice, Tg miceExpression of these constructs in cultured cells showed
induced for 8 or 12 weeks exhibited a 25% or 40%that both p25-GFP and p25-Cmyc behave similarly in
decrease in cortical neuronal density, respectively. Thethat their subcellular localization and ability to activate
neuronal density was indistinguishable between WT andCdk5 was identical to that of untagged p25 (data not
noninduced Tg mice (Figure 2F), indicating that the neu-shown). We further characterized independent Tg mouse
ropathology observed in p25 Tg mice is due to degener-lines expressing p25-GFP and p25-Cmyc and found that
ation in adulthood caused by postnatal p25 inductionboth Tg mouse lines had similar expression profiles and
and is not attributed to minimal p25 expression priorphenotypes. These cumulative results demonstrate that
to induction.the epitope tags themselves neither interfere with the
Reactive astrogliosis often accompanies neuronalbiological activity of p25 nor are they responsible for
loss and serves as a hallmark lesion for neurodegenera-the phenotypes we observe.
tion. A remarkable increase in GFAP-immunoreactiveIn forebrains of induced p25-GFP Tg mice, robust
radial and stellate-shaped astrocytes was quite evidentp25 transgene expression was detected as compared
throughout the cortex and hippocampus of p25 Tg miceto forebrains of wild-type (WT) and noninduced p25 Tg
(Figure 2G). Certain neurons were also positive for activemice (Figure 1A). Cdk5, p35, p39, and -actin expression
caspase-3 in the cerebral cortex of Tg mice (Figure 2H).were similar in all mice (Figure 1A). Upon dissection of
In the dentate gyrus of the hippocampus, there was anvarious brain regions from control and induced Tg mice,
overlap among those neurons that expressed p25 andimmunoblot analysis revealed substantial p25 expres-
were positive for active caspase-3 (Figure 2I). Neithersion and induction in the cerebral cortex, hippocampus,
active caspase-3 nor GFP staining was found in controland striatum with minimal p25 expression in the cerebel-
mice. These immunohistochemical results were furtherlum of induced Tg mice (Figure 1B). Either low or no
corroborated by immunoblot analysis. Increases in bothp25 expression was found in noninduced Tg and WT
GFAP and active caspase-3 immunoreactivities weremice, respectively (Figure 1B). Similar results were also
found in forebrain, but not hindbrain, lysates from Tgfound in the p25-Cmyc Tg mouse line (see Supplemental
mice (Figure 2J). Together, these results indicate thatFigures S1A and S1B at http://www.neuron.org/cgi/
the age-dependent neuronal loss, accompanied by ex-content/full/40/3/471/DC1). Our results are consistent
tensive astrogliosis and caspase-3 activation, occurswith those from previous studies using the CamKII-tTA
with a selective pattern of degeneration that correlatesmice to inducibly express other transgenes (Mayford et
with p25 expression in Tg mice.al., 1996; Yamamoto et al., 2000). We next determined
the subcellular localization of the p25-GFP transgene
with anti-GFP to distinguish p25 from endogenous p35. Increased Cdk5 Activity and Differential Substrate
Phosphorylation in p25 Tg MiceWe found that p25 displayed a somatodendritic staining
pattern in neurons of the cerebral cortex and the hippo- We next sought to determine if neurodegeneration was
triggered by increased Cdk5 activity in p25 Tg mice.campus (Figure 1C). Unlike the localization of p35 (De-
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Figure 1. Brain Regional p25 Expression and Cdk5 Activation
(A) Immunoblot analysis of WT, induced (Tg-On), and noninduced (Tg-Off) Tg mouse forebrain lysates.
(B) Immunoblot analysis of WT, Tg-On, and Tg-Off mouse brain lysates derived from cortex (ctx), hippocampus (hip), cerebellum (cer),
hypothalamus (hyp), or striatum (str). Ratios of p25-GFP/p35 were determined by densitometry analysis.
(C) GFP immunoreactivity in the cerebral cortex (upper panels) and CA1 region of the hippocampus (lower panels) from WT and Tg-On mice.
All Tg mice were induced, or noninduced, for 5 weeks except (C), which were induced for 8 weeks.
Two different p35 antibodies were used to immunopre- Other Cdk5 substrates are known to be involved in
various physiological events. Nudel is a Lis1 and cyto-cipitate the active Cdk5 complex. Using the C19 anti-
body recognizing the C termini of p35 and p25, there plasmic dynein binding protein that is phosphorylated
by Cdk5 at multiple sites (Niethammer et al., 2000; Sa-was a significant increase (2.3  0.1) in Cdk5 activity in
induced Tg mice as compared to WT mice (Figure 3A). saki et al., 2000). mDab1 is a key component in the Reelin
signaling pathway essential for neuronal positioning andNo differences were found between WT and noninduced
Tg mice. When the N20 antibody, which recognizes the is phosphorylated by Cdk5 at S496 (Keshvara et al.,
N terminus of p35 not present in p25, was used, no 2002). PSD95 is a postsynaptic scaffolding protein im-
significant differences were seen among control and Tg portant for the assembly of signaling and cytoskeletal
mice (Figure 3A). These results demonstrate that p25 components. PSD95 is phosphorylated by Cdk5 on T19
Tg mice conditionally express high levels of p25, which and S25 (Yang and Hinds, 2003). By Western blot analy-
results in elevated p25/Cdk5 activity without affecting ses of forebrain lysates using phospho-epitope-specific
endogenous p35/Cdk5 activity. antibodies against Cdk5 phosphorylation sites of Nudel,
Another means to assess Cdk5 activity is to examine mDab1, and PSD95, no increases in phosphorylation of
the phosphorylation status of known Cdk5 substrates. these proteins was observed (Figure 3C). Phosphoryla-
Cdk5 is associated with the phosphorylation of proteins tion at these sites was abolished or diminished in p35
implicated in neurodegenerative diseases. In addition and Cdk5-deficient mice (Keshvara et al., 2002; Ko et al.,
to tau, neurofilament H (NFH) (Hisanaga et al., 1995) and 2001). The differential phosphorylation activities toward
-amyloid precursor protein (APP) (Iijima et al., 2000) these sets of substrates support the notion that p25
have been shown to be phosphorylated by Cdk5. Immu- exhibits altered substrate specificity from that of p35.
noblot analysis using SMI34, recognizing phosphory-
lated NF, showed a marked increase in NF phosphoryla-
Tau Hyperphosphorylation and Microtubuletion in Tg mice as compared to WT mice. Conversely,
Polymerization in p25 Tg Micethere was a decrease in the amount of unphosphory-
We next examined whether increased p25/Cdk5 activitylated NF in Tg mice when immunoblotted with SMI32,
affects endogenous tau phosphorylation in p25 Tg mice.recognizing unphosphorylated NF (Figure 3B). In Tg
Western blot analysis of WT and Tg forebrain lysatesmice, phosphorylation of T668 in the cytoplasmic do-
showed that total levels of tau were similar (Figure 4A).main of APP was considerably higher than in control
littermates (Figure 3B). Increased phosphorylation of tau at several epitopes
Neuron
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Figure 2. Progressive Neurodegeneration in the Cerebral Cortex and Hippocampus
(A) Substantial forebrain atrophy in 12 week induced Tg compared to WT littermate.
(B) Significant reductions in brain mass in Tg mice. Whole brains from mice were dissected and weighed. Error bars represent SEM values
for WT and Tg-Off littermates (n  3); WT and Tg-On littermates induced for 5 weeks (n  5), 7–8 weeks (n  11), or 12 weeks (n  5). p
values (**p  0.005; ***p  0.0001) were determined using a two-tailed, nonparametric, unpaired Student’s t test.
(C) Decrease in thickness and neuronal density in the cortex (upper panels) and dentate gyrus of the hippocampus (lower panels) in induced
Tg mice. Coronal brain sections from Tg-Off and Tg-On littermates, noninduced or induced for 12 weeks, were stained with Nissl and Luxol
fast blue.
(D and E) Progressive neuronal loss in the cortex (D) and hippocampus (E) of Tg mice. Coronal brain sections from WT or Tg-On mice induced
for 8 or 12 weeks were immunostained with the neuron-specific marker, NeuN. The same results were found when brain sections were
immunostained with HuC/D.
(F) Quantification of neuronal loss in induced and noninduced Tg mice as compared to WT mice. The neuronal density was determined as
described in Experimental Procedures. p values: *p  0.05; ***p  0.0001.
(G) Increased GFAP staining in the cerebral cortex (upper panels) and hippocampus (lower panels) from 8 week induced Tg mice compared
to WT mice. Insets represent higher magnification views.
(H) Increased active caspase-3 staining in the cerebral cortex from 8 week induced Tg mice compared to WT mice.
(I) Active caspase-3 staining in the dentate gyrus of the hippocampus from WT and 8 week induced Tg mice. An adjacent Tg brain section
was also immunostained with anti-GFP.
(J) Increased GFAP and active caspase-3 immunoreactivity in Tg brain regions highly expressing p25. Immunoblot analysis was performed
on WT and 7 week induced Tg mice.
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Figure 3. Cdk5 Activity and Differential Cdk5 Substrate Phosphorylation
(A) Increased Cdk5 activity in Tg mice. Values for Tg-On and Tg-Off mice were calculated relative to WT control littermates. Error bars represent
SEM values for WT (n  4), Tg-On (n  4), and Tg-Off (n  3) Tg mice. p values: **p  0.005.
(B and C) Increased phosphorylation of pathological, but not physiological, Cdk5 substrates in Tg mice. Immunoblot analysis of WT and Tg
mice was performed using antibodies and specific phospho-epitope antibodies to NF, APP, Nudel, mDab, and PSD95. The fold increase
(relative to WT) represents the average of two or more independent experiments from at least two different pairs of WT and Tg littermates.
In (A)–(C), forebrain lysates from Tg mice induced, or noninduced, for 5 weeks were analyzed.
in Tg mice was detected by immunoblotting with the preparations derived from Tg mice were used, we found
that these mice were compromised in their ability toantibodies AT8 (Figure 4B) and PHF1 (Figure 4C). Immu-
nohistochemical analysis using these phospho-tau form stable microtubules (Figure 4F).
antibodies identified irregular, cytoplasmic dense tau
inclusions within neurons of the cerebral cortex and Tau Aggregation in p25 Tg Mice
Aggregated, NFT-like tau derived from overexpressionpyramidal cells of the hippocampus of Tg mice that was
not present in WT mice (Figure 4D and see Supplemental of human mutant tau in Tg mice has been shown to
be enriched in sarkosyl-insoluble fractions (Allen et al.,Figure S1E at http://www.neuron.org/cgi/content/full/
40/3/471/DC1). 2002; Lewis et al., 2000, 2001). To examine if endoge-
nous mouse tau can form similar tau aggregates, weTo obtain a more comprehensive picture of the tau
phosphorylation profile in p25 Tg mice, we performed isolated these fractions from forebrains of 8 and 12 week
induced p25 Tg mice and found a substantial portiontandem mass spectrometry on heat-stable soluble tau
preparations derived from WT and Tg mice. Although of tau localized to the sarkosyl-insoluble fraction (Figure
5A). Moreover, phosphorylation of tau, as revealed byphospho-tau peptides were detected in both WT and Tg
mice, the phospho-tau peptide profiles obtained were AT8 antibody, in these fractions, was considerably in-
creased in 12 week induced Tg mice (Figure 5A). Wedifferent between the samples, with only a few regions
of overlap (Figure 4E). These results suggest that the also analyzed the p25-Cmyc Tg mouse line that displays
similar phenotypes as those described for the p25-GFPphosphorylation pattern of tau is significantly changed
in Tg mice. A total of 6 phosphorylated tau sites in Tg mouse line (see Supplemental Figure S1 at http://
www.neuron.org/cgi/content/full/40/3/471/DC1). InWT and 15 phosphorylated tau sites in Tg mice were
identified (Table 1). Tau peptides containing phosphory- Tg mice induced for 15 weeks, there was less soluble
tau with a concomitant increase in insoluble tau as com-lated S202, T205, and T396 were found only in Tg mice,
supporting our results using AT8 and PHF1 antibodies pared to control mice (Figure 5B). Similar results were
also found in forebrains of 27 week induced Tg mice,(Figures 4B–4D). The presence of other tau peptides
containing phosphorylated proline-directed and non- in which insoluble tau accumulated and could be de-
phosphorylated upon phosphatase treatment (Figureproline-directed phosphorylation sites were also de-
tected in Tg mice. 5C). Furthermore, in hindbrains, which express low p25
levels, of these animals, no accumulation of tau wasOne physiological role of tau is to aid in the polymer-
ization of tubulin to form stable microtubules. When observed (Figure 5C). These observations demonstrate
that tau aggregation progressively and selectively devel-hyperphosphorylated, tau can no longer efficiently bind
to microtubules, thereby inhibiting the formation of poly- ops in p25 Tg mice.
Considering the accumulation of aggregated tau in Tgmers of microtubules. To determine if this function of
tau is compromised in p25 Tg mice, we performed a mice, we next examined the ultrastructure of the sarkosyl-
insoluble fractions using transmission electron micros-microtubule polymerization assay. Over time, tubulin
alone, without tau-containing lysates, did not efficiently copy. As shown by tau5 and 5E2 immunogold labeling,
numerous tau immunoreactive filaments were identifiedpolymerize into microtubules (Figure 4F). When heat-
stable tau preparations derived from WT forebrains were that had a diameter between 10 and 20 nm (Figures 5D
and 5E). Tau aggregates prepared from 1-year-old Tgadded to tubulin, efficient microtubule polymerization
was observed (Figure 4F); however, when similar tau mice expressing the human tau P301L mutation (Lewis
Neuron
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Figure 4. Tau Hyperphosphorylation
(A–C) Immunoblot analysis of 5–7 week fore-
brain lysates from WT and Tg mice using tau
and phospho-tau antibodies. Using tau5 rec-
ognizing total tau, no apparent differences
were observed. (A) Using antibodies recog-
nizing specific phospho-epitopes of tau, such
as AT8 (B) and PHF-1 (C), significant in-
creases in tau hyperphosphorylation were
found in Tg mice.
(D) Immunohistochemical phospho-tau stain-
ing in WT and 12 week induced Tg mice. In
Tg mice, an abundant number of neurons in
the cerebral cortex were immunostained with
PHF1 (upper panels) and in the CA2 region
of the hippocampus with AT8 (lower panels).
Insets represent higher magnification views.
(E) Mass spectrometry analysis of heat stable
tau preparations from WT and 5 week in-
duced Tg forebrains. A partial protein se-
quence of the mouse tau protein shows the
phosphorylated peptide coverage map. The
numbering is based on human tau that is 441
amino acids long. Tau phosphopeptides de-
tected are in green (WT), red (Tg), and blue
(overlap of WT and Tg). Results shown are
representative of two independent experi-
ments.
(F) Microtubule polymerization assay. Heat
stable tau preparations derived from fore-
brains of Tg mice show a marked decrease
over time in polymerizing tubulin to form sta-
ble microtubules as compared to WT mice.
Results shown are representative of two inde-
pendent experiments.
et al., 2000) exhibited similar morphology to that of the The aggregated tau filaments derived from both p25 and
tau P301L Tg mice were also positive for phospho-taup25 Tg mice (Figure 5D). No immunogold labeling of
these structures was found in WT mice (data not shown). epitopes, including AT8 and PHF1 (Figure 5E). Further-
Table 1. Summary of Mouse Phospho-Tau Peptides Detected in Tandem Mass Spectrometry
Peptides Sequences Phosphorylations
WT
103–130 EEAGIGDTPSLEDEAAGHVTQARMVSK Thr111
171–194 IPAKTTPSPKTPPGSGEPPKSGER Thr175, Thr176, Thr181, Ser185
226–242 VAVVRTPPKSPSASKSR Thr231
p25 Tg
171–180 IPAKTTPSPK Thr175, Thr176, Ser178
195–224 SGYSSPGSPGTPGSRSRTPSLPTPPTREPK Ser195, Ser198, Ser199, Ser202, Thr205
210–221 SRTPSLPTPPTR Thr217, Thr220
210–224 SRTPSLPTPPTREPK Thr217, Thr220
212–221 TPSLPTPPTR Thr217
235–257 SPSASKSRLQTAPVPMPDLKNVR Ser235, Ser239
386–406 TDHGAEIVYKSPVVSGDTSPR Ser396, Ser400, Thr403
Phosphorylated residues are labeled in bold font. The numbering in the mouse tau peptide sequences are based on human tau with 441
amino acids.
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Figure 5. Sarkosyl-Insoluble Tau
(A) Accumulation of sarkosyl-insoluble tau in
p25-GFP Tg mice. Immunoblot analysis of WT
and Tg mice induced for 8 or 12 weeks was
performed using tau5 and AT8 antibodies.
(B) Accumulation of sarkosyl-insoluble tau in
p25-Cmyc Tg mice. Immunoblot analysis of
WT and Tg mice induced for 15 weeks was
performed using tau 5 antibodies. In (A) and
(B), the asterisk indicates the presence of a
68 kDa tau isoform. This immunoreactive tau
species indicates the presence a hyperphos-
phorylated tau species that resembles a 68
kDa tau isoform known to exist in human AD
brains and is a defining component of NFTs
(Lee et al., 1991; Wolozin et al., 1986).
(C) Accumulation of sarkosyl-insoluble tau in
p25-GFP Tg mice. Immunoblot analysis, us-
ing tau 5 antibodies, of WT and Tg mice in-
duced for 27 weeks, was performed. No 68
kDa tau isoform was found in these lysates;
however, tau was dephosphorylated when
treated with phosphatase for 1 hr at 37C and
immunoblotted with tau 1 antibodies, recog-
nizing unphosphorylated tau.
(D and E) Immunoelectron microscopy of sar-
kosyl-insoluble fractions from p25 and tau
P301L Tg mice. Sarkosyl-insoluble fractions
from (B) or from forebrains of 1-year-old tau
P301L Tg mice were similarly decorated with
antibodies tau5 and 5E2 antibodies, recog-
nizing unphosphorylated and phosphorylated
tau (D), and AT8, PHF1, and TG3 antibodies,
recognizing phospho-tau epitopes S202/
T205, S396/S404, and an abnormal hyper-
phosphorylated confirmation state of tau, re-
spectively (E).
more, tau filaments from both sets of Tg mice were longer induced p25 Tg mice but not in WT littermates
(Figures 6A–6I, data not shown). NFT-like structuresdecorated with the TG3 antibody (Figure 5E), a confor-
mation-specific tau antibody recognizing hyperphos- were found in the cortex of Tg, but not WT, as revealed
by Bodian silver staining (Figure 6J). Gallyas silver stain-phorylated tau in an abnormal conformation state.
ing, a more specific stain for neurofibrillary structures,
showed more silver-positive cells in the cortex and, toNeurofibrillary Pathology in p25 Tg Mice
a lesser extent, the hippocampus of Tg mice (FiguresIn post mortem brains of human AD patients and mutant
6K–6N). We further observed neurons in the cortex, en-tau Tg mice, the presence of specific structural and
torhinal cortex, and hippocampus of Tg mice that werebiochemical properties of NFTs can be demonstrated
positive for Thioflavin-S, a marker for late stage tanglesthrough the combined use of NFT-specific antibody,
(Figures 6O–6R). No silver- or Thioflavin-S-positivesilver, and Thioflavin-S stainings (Lewis et al., 2000; Sun
structures were seen in WT or Tg mice induced for eitheret al., 2002). To examine whether p25 Tg mice display
8 or 12 weeks (data not shown). Immunogold labelingNFT-like pathology, we used these methods to analyze
of sarkosyl-insoluble tau filaments from p25 and P301LTg mice that had been induced for over 27 weeks. Both
tau Tg mice were morphologically indistinguishable andlight and fluorescence microscopy showed numerous
similarly labeled with AT8 (Figures 6S–6T) and AT100AT8- and AT180-positive intraneuronal and flame-
shaped neurons in the cortex and hippocampus of (data not shown). Our cumulative results demonstrate
Neuron
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Figure 6. NFT Pathology
(A–I) Light and immunofluorescence microscopy using AT8 (A–D) and AT180 (S231) (E–I) antibodies in the cortex (A and B and E–H) and
hippocampus (C, D, and I) of WT and Tg mice.
(J–N) Silver staining using Bodian (J) and Gallyas (K–N) stains in the cortex (J–L) and hippocampus (M) of WT and Tg mice. Higher magnification
of the boxed area in (L) is in (N).
(O–R) Thioflavin-S staining in the cortex (O–P), entorhinal cortex (Q), and hippocampus (R) of WT and Tg mice.
(S and T) AT8 immunogold electron microscopy of p25 Tg forebrain and 1-year-old P301L tau Tg hindbrain/brainstem. In (A)–(S), all Tg mice
analyzed were induced for 27–30 weeks and compared to same-sex littermate WT mice. All scale bars are 25 m.
that aberrant Cdk5 activity caused by p25 accumulation logical changes and severe atrophy of the forebrain are
readily apparent. After 12 weeks of p25 induction, aboutinduces the formation of endogenous tau filaments in
the cortex and hippocampus of mice. 40% of neurons are lost in the cortex and hippocampus.
It is possible that the cortico-limbic distribution of pa-
thology in these mice may reflect the distribution ofDiscussion
expression with the CamKII promoter. It has been pre-
viously shown that p25 induces apoptotic cell death inThe p25 Tg mice described in this study represent an
in vivo paradigm to study the role of p25 accumulation primary cultures and other cell lines (Ahuja et al., 1997;
Patrick et al., 1999; Zhang et al., 2002). Using an inhibitorand aberrant Cdk5 activity in neurodegeneration and
tau pathology progression. We report that inducible p25 of caspase-3, p25/Cdk5-induced nuclear fragmentation
can be partially inhibited (Patrick et al., 1999). We showexpression increases Cdk5 activity and results in sub-
stantial brain atrophy and progressive neuronal loss. here that active caspase-3, a downstream effector of
apoptosis, strongly correlates with p25 expression, fur-Deregulated Cdk5 activity also leads to the hyperphos-
phorylation and accumulation of aggregated tau, which ther suggesting that apoptotic machinery may be acti-
vated by p25 in vivo. A direct link between p25 andprecedes the formation of NFT-like structures. We pres-
ent a mouse model that shows tauopathy derived from apoptotic machinery, however, still remains to be estab-
lished.endogenous tau and increased kinase activity. Notably,
these degenerative and pathological features are closely Due to the different biochemical properties and sub-
cellular localizations of p25 and p35, these regulatoryassociated with the cerebral cortex and hippocampus,
the major brain regions affected in several human neuro- proteins may preferentially direct Cdk5 toward specific
subsets of substrates. The p25/Cdk5 complex, as com-degenerative disorders, including frontotemporal de-
mentias and AD. pared to the p35/Cdk5 complex, more efficiently phos-
phorylates tau in vitro (Hashiguchi et al., 2002; PatrickA prominent feature of our p25 Tg mice is the progres-
sive loss of neurons and extensive astrogliosis. Remark- et al., 1999). Our observations in p25 Tg mice further
support this idea, as an increase in p25/Cdk5, but notably, several weeks after p25 induction, gross morpho-
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p35/Cdk5, activity upregulates phosphorylation of tau may be the existence of distinct mechanisms for the
pathological development of normal versus mutant tau.and other proteins associated with neurodegeneration,
such as APP and NF. Overexpression of p35 in Tg mice, The accumulation of sarkosyl-insoluble tau and NFTs
has been previously reported for Tg mice overexpress-despite an increase in Cdk5 activity, does not lead to
tau hyperphosphorylation (Van den Haute et al., 2001). ing human mutations of tau found in frontotemporal
dementias (Allen et al., 2002; Lewis et al., 2000; NobleWe also find that p25 Tg mice do not display increases
in phosphorylation of Nudel, mDab1, and PSD95, al- et al., 2003). In these mice, tauopathies are mostly local-
ized to the brainstem and spinal cord, areas of the cen-though in p35 and Cdk5-deficient mice, phosphorylation
of these substrates is either diminished or abolished. tral nervous system relatively unaffected in frontotem-
poral dementias and AD. This may be due to the differentTaken together, these observations suggest that there
are different subsets of Cdk5 substrates that can be promoters utilized to generate these Tg mice. Here, we
demonstrate that increased Cdk5 activity leads to insol-influenced by p25 or p35 in vivo.
Cdk5 phosphorylates several epitopes of tau in vitro uble aggregation and fibrillization of endogenous tau in
the cortex and hippocampus of p25 Tg mice, showingthat are also hyperphosphorylated in AD brains and is
thought to play a role in the transformation of tau into a striking resemblance to the prolyl isomerase Pin1
knockout mice (Liou et al., 2003). Because no geneticNFTs. Here, we show that in p25 Tg mice, these epitopes
of endogenous tau are hyperphosphorylated in vivo. mutations in tau have been found in human AD patients
to date, our finding that p25 induces tau pathology de-Our results from tandem mass spectrometry analysis,
coupled with that data using AT8 and PHF1 antibodies, rived from endogenous tau underscores a role for p25/
Cdk5 in influencing the progression of neurofibrillarydemonstrate tau epitopes at S202, T205, and S396 are
phosphorylated in p25 Tg mouse brains. Other proline- pathology in AD. Furthermore, our study complements
previous mouse and fly models of neurodegenerationdirected residues, S178, S199, T217, and S235 are phos-
phorylated upon p25 induction, suggesting that phos- to provide further evidence for the general importance
of protein phosphorylation and aberrant kinase activityphorylation at these sites may be mediated through p25/
Cdk5 and/or other proline-directed kinases. Nonproline- in the formation of NFTs and neurodegeneration (Jack-
son et al., 2002; Lucas et al., 2001; Noble et al., 2003).directed sites of tau phosphorylated in p25 Tg mice
include S198, S239, S400, and T403. Phosphorylation Our p25 Tg mice share many of the features of human
tauopathies and AD in that they display progressiveof these epitopes is also found in paired helical forma-
tions of tau. Due to the abundance and ionization effi- neurodegeneration, accumulation of hyperphosphory-
lated, and aggregated tau, and NFT-like pathology. Inciency of the phospho-peptides, our mass spectrometry
analysis may not have detected all phospho-tau pep- these animals, hyperphosphorylation and aggregation
of tau coincides with onset of neuronal loss, which oc-tides. It is also possible that altered phosphatase activi-
ties (Liou et al., 2003) contribute to our results. Nonethe- curs prior to formation of late stage tangles. These re-
sults argue, at least in terms of tau, that neurotoxicityless, a direct comparison of WT and Tg mice indicates
a profound effect of p25/Cdk5 on tau hyperphosphor- may result from abnormal tau metabolism that precedes
tau filament formation. This argument is further sup-ylation. These findings also provide evidence for the
involvement of p25/Cdk5 in activating other kinases that ported by a fly model of tauopathy (Wittmann et al.,
2001) and some human patients with frontotemporallead to tau hyperphosphorylation.
Cdk5 has been shown to modulate the activity of sev- dementia who present substantial neurodegeneration
with little NFT pathology (Bird et al., 1999). Other thaneral protein kinases involved in tau hyperphosphoryla-
tion (Li et al., 2002; Sharma et al., 2002). We find that tauopathy, additional p25-induced pathological events
are likely to contribute to neurodegenerative processesthe p42/44 MAP kinases, which have been shown to be
involved in the progression of tau pathology and are in p25 Tg mice.
The neurodegeneration phenotype and increased tauupregulated in AD brains (Zhu et al., 2002), are activated
in p25 Tg mice (see Supplemental Figures S2A and S1B hyperphosphorylation in our p25 Tg mice are in contrast
to previously published p25 Tg mice. Expression of hu-at http://www.neuron.org/cgi/content/full/40/3/471/DC1).
We also find increased phosphorylation of FAK at Y397 man p25 under the NSE promoter leads to hyperphos-
phorylation of tau and NF as examined by immunostain-in p25 Tg mice (see Supplemental Figure S2B). Aberrant
activation of FAK at Y397 mediates fibrillary A-induced ing; however, no difference is found by Western analysis
(Ahlijanian et al., 2000). Similar results are found withneuronal dystrophy and tau hyperphosphorylation
(Grace and Busciglio, 2003; Williamson et al., 2002). the PDGF promoter (Bian et al., 2002). When bovine p25
is driven by the CMV promoter, no hyperphosphorylationGSK-3 is another kinase intimately involved in tau
phosphorylation. When examining GSK-3 activity in of tau is seen (Takashima et al., 2001). No neuronal death
in the cortex or hippocampus is associated with any ofour p25 Tg mice, we find that its activity is not upregu-
lated (see Supplemental Figure S2C). GSK-3 Tg mice these p25 Tg animals. One reason for these discrepanc-
ies may be that the inducible p25 Tg mice described inshow tau hyperphosphorylation but no NFTs (Lucas et
al., 2001). Together, these results suggest that Cdk5 this study are under the control of the CamKII promoter,
which drives high p25 expression in the forebrain. It isand GSK-3 may lie in separate pathways that lead to
tau hyperphosphorylation or NFT formation. A recent possible that there are factors present in the forebrain
that need to work in concert with p25 to cause taustudy describes that hyperphosphorylation and aggre-
gation of mutant P301L tau may be caused by an in- pathology. In addition, our Tg mice inducibly express
p25 postnatally and not constitutively throughout devel-crease in both Cdk5 and GSK-3 activity (Noble et al.,
2003). Since our p25 Tg mice display pathology derived opment. As such, there may be no developmental com-
pensation that compromises the toxicity of p25. Anotherfrom normal tau, one explanation for this discrepancy
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Figure 7. Model
We propose a model describing the various
pathogenic events triggered by p25 and aber-
rant Cdk5 activity under neurotoxic condi-
tions. See text for details.
reason underlying the differences may be that our p25 ible p25 Tg mice provides unequivocal evidence that
Tg mice exhibit higher p25 levels and Cdk5 activity than p25 accumulation in vivo causes neuronal death and
other p25 Tg mice. Neurodegeneration most likely corre- tau pathology. Our p25 Tg mice represent a valuable
lates with high levels of p25 accumulation, since we model for therapeutic intervention of neurodegenerative
observe neuropathology only in those brain regions ex- diseases, providing an impetus to develop strategies
pressing high levels of p25. Further evidence to support to specifically inhibit p25 accumulation and aberrant
this notion is that we characterized another line of induc- Cdk5 activation.
ible p25 Tg mice that expresses p25 several fold less
than the mouse lines described here. Interestingly, al-
Experimental Proceduresthough the spatial expression of p25 is similar, no neuro-
degeneration is observed in these mice when p25 ex- Generation of p25 Tg Mice
pression is induced for similar times as described for Human p25 (Patrick et al., 1999) was C-terminally tagged with GFP
the p25 Tg mice in this study (data not shown). This or Cmyc, subcloned into pTet-Splice (Clontech), and verified by
sequencing. Plasmid vectors were linearized with XmnI and digestedfinding is consistent with a recent study describing the
with XhoI/NotI to release TetO-p25-GFP or TetO-p25-myc. Eachexpression of very low levels of p25 in mice (Angelo et
p25 transgene was microinjected into fertilized mouse eggs andal., 2003).
reimplanted into pseudopregnant females. Founders were screenedWe propose the following working model based on
by Southern blot and PCR. Germline founders were crossed with
previous studies and our current findings (Figure 7). Vari- CamKII-tTA Tg mice (Mayford et al., 1996). All mice were back-
ous neurotoxic insults result in p35 cleavage by calpain crossed to obtain a homogeneous C57BL/6J background. Mice for
to generate p25 and deregulate Cdk5 activity. These insults analysis were derived from heterozygote crosses to ensure all geno-
are likely to be early events in the progression of neuro- types in each litter, which were obtained in a Mendelian manner.
All mice in this study were conceived (throughout gestation) anddegenerative diseases. Over time and above a threshold
raised in the presence of doxycycline (up to 1 mg/g in food, changedlevel, p25 accumulation triggers a cascade of pathologi-
twice a week) (Bio-Serv, Frenchtown, NJ) for at least 4–6 weekscal events. This may be due in part to the different
postnatal before induction of p25 (by removal of doxycycline) to
substrate specificities of p25 and p35 that arise from prevent any potential developmental consequences from the ex-
their different biochemical properties and subcellular pression of p25. Littermate and same sex mice were used for com-
localizations. One consequence of p25 accumulation is parison whenever possible.
neuronal loss, which most likely results from the activa-
tion of multiple cell death mechanisms. In addition,
Cdk5 Kinase Assaydysregulated Cdk5 activity by p25 causes aberrant
Mice were sacrificed by cervical dislocation. Brains were dissectedtau metabolism that leads to its hyperphosphorylation,
and homogenized in RIPA buffer (50 mM Tris, pH 8.0, 150 mM
disruption of its association with microtubules, and its NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS) containing
increased aggregation. These pathogenic tau events ul- protease and phosphatase inhibitors. Brain lysates (500 g) were
timately culminate in neurofibrillary pathology. Interest- incubated with p35 (1g) antibodies from Santa Cruz Biotechnology
(Santa Cruz, CA) for 1 hr at 4C and the active Cdk5 complex wasingly, given that A can induce p25 generation suggests
isolated with PAS for 1 hr at 4C. The immunocomplex was subjectedthat Cdk5 may act as a molecular link between plaques
to a Cdk5 kinase assay using histone H1 peptide (PKTPKKAKKL)and tangles, the two invariant hallmarks of AD. Abnormal
as a substrate. Once a reaction mixture, containing 20 mM MOPSactivation of Cdk5 by p25 may also alter other signaling
(pH 7.2), 5 mM MgCl2, 500 M H1 peptide, 100 M ATP, and 2.5pathways that, in turn, contribute to pathogenesis. The
Ci -32ATP, was added, the reaction continued for 20 min at RT.
precise relationship between NFT pathology and neuro- The reaction was stopped by placing samples on ice for 5 min.
degeneration, however, remains to be elucidated. Supernatants were spotted on P-cellulose discs, washed in 0.3%
phosphoric acid, and counted in a liquid scintillation counter.In summary, the phenotype manifested in our induc-
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Immunoblot Analysis Microtubule Polymerization Assay
Lyophilized tubulin from Cytoskeleton (Denver, CO) was reconstitu-Brain lysates were prepared as described above. Lysates were used
freshly, or aliquoted, frozen in liquid nitrogen, and stored at 	80C ted in G-PEM buffer, as described by the manufacturer, at 4C and
centrifuged to remove tubulin aggregates. To perform the in vitrountil use. Note that the phosphorylation status of several substrates
was sensitive to storage at 	80C. Equal amounts of brain lysates tubulin assembly assay, 0.5 mg/ml of tubulin was added to 0.2 mg/
ml of mouse forebrain heat-stable tau preparations in G-PEM buffer.were subjected to SDS-PAGE and Western blot analysis. The follow-
ing antibodies (diluted 1:1000 unless otherwise noted) were used: Tubulin assembly was monitored once room temperature was
reached. Similar amounts of tau protein in the heat-stable prepara-monoclonal DC17 (Cdk5) (1:10), polyclonal antibodies p35, p39,
P-Nudel (S231), P-mDab1 (S491), P-PSD95 (S19/S25), and P-APP tions were confirmed by Western analysis. The turbidity measure-
ment of tubulin polymerization was monitored in a Beckman DU640(T668) generated in the Tsai lab; actin and GFAP from Sigma (Saint
Louis, MO); PSD95, cleaved caspase-3 Asp175 (1:500), p42/44, Spectrophotometer at 350 nm.
P-p42/44 (T202/Y204), and P-GSK-3 (S9) from Cell Signaling Tech-
nology; FAK, JNK1, and P-JNK (T183/Y185) from Santa Cruz Tech- Sarkosyl-Insoluble Fractionation
nology; P-GSK-3a/ (Y279/216) and tau 5 from Biosource Interna- Fractionation from forebrain halves was performed based on meth-
tional (Camarillo, CA); -catenin from Becton, Dickinson, and ods previously described (Lewis et al., 2001). Equal amounts (v/w)
Company (Franklin Lakes, NJ); tau1 (1:2000) from Chemicon Interna- were subjected 8% SDS-PAGE and Western analysis.
tional (Temecula, CA); AT8 from Innogenetics (Belgium); and PHF1
from P. Davies. Electron Microscopy
Samples were placed on 200 mesh copper Formvar/carbon-coated
grids exposed to glow discharge. After blocking in 1% BSA, samples
Immunohistochemical and Histochemical Studies were incubated in primary antibody, followed by a rabbit anti-mouse
Mice were anesthetized with avertin and intracardially perfused with bridging antibody. Bound antibodies were visualized by 10 nm PAG,
PBS, followed by 4% paraformadehyde. Comparable 6 m thick stained with 1% uranyl acetate, and viewed with a JEOL 1200EX
paraffin coronal brain sections were deparaffinized and rehydrated. transmission electron microscope. The following antibodies were
Antigen retrieval was performed by microwave irradiation. For cer- used for immunogold labeling. Phosphorylation-independent tau
tain immunostains, 88% formic acid treatment was also performed. antibodies (1:5–1:10) include tau5 from Biosource International (Ca-
Sections were incubated with primary antibodies overnight at 4C. marillo, CA) and 5E2 from K. Kosik. Phosphorylation-dependent tau
Bound antibodies were detected by standard streptavidin-biotin- antibodies include monoclonal antibodies AT8 from Innogenetics
peroxidase methods (Vector Laboratories, Burlingame, CA) or by (Belgium) and PHF1 and TG3 from P. Davies.
immunofluorescence. The following antibodies were used for immu-
nostaining: GFP (1:1000) and HuC/D (10 g/ml) from Molecular Acknowledgments
Probes (Eugene, OR); NeuN (1:500) from Chemicon International;
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